Arthritic Therapeutic Market Report 2026
Global Outlook – By Drug Class (Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Topical), By Type (Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2030
Arthritic Therapeutic Market Overview
• Arthritic Therapeutic market size has reached to $72.44 billion in 2025 • Expected to grow to $97.09 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Increasing Incidence Of Arthritis Is Driving The Growth Of The Arthritic Therapeutic Market • Market Trend: Innovative Biosimilar Monoclonal Antibody Therapies Enhanced Arthritis Therapeutic Market • North America was the largest region in 2025.What Is Covered Under Arthritic Therapeutic Market?
Arthritic therapeutics refer to treatments designed to alleviate symptoms and improve quality of life for individuals with arthritis. This includes medications, physical therapy, and other interventions aimed at reducing pain, inflammation, and joint damage. These therapies can help manage various forms of arthritis, such as osteoarthritis and rheumatoid arthritis. The main drug classes of arthritic therapeutic are tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, xanthine oxidase inhibitors, and others. Tumor necrosis factor (TNF) inhibitors are a class of drugs that block the action of TNF, a protein involved in inflammation, to treat autoimmune diseases They are administered through oral, parenteral, and topical routes for various types of arthritis, such as psoriatic arthritis, rheumatoid arthritis, osteoarthritis, and gout. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
What Is The Arthritic Therapeutic Market Size and Share 2026?
The arthritic therapeutic market size has grown strongly in recent years. It will grow from $72.44 billion in 2025 to $77 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising prevalence of arthritis worldwide, increasing geriatric population, limited access to advanced therapeutics, growing awareness of arthritis management, expansion of hospital and clinic infrastructure.What Is The Arthritic Therapeutic Market Growth Forecast?
The arthritic therapeutic market size is expected to see strong growth in the next few years. It will grow to $97.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of novel biologics and targeted therapies, increasing adoption of telemedicine and remote patient monitoring, integration of digital health platforms, rising investment in arthritis research and clinical trials, growth in personalized medicine approaches for arthritis. Major trends in the forecast period include rising adoption of biologic and targeted therapies for arthritis, increasing preference for personalized arthritis management plans, growth in home-based physical therapy and rehabilitation services, expansion of online pharmacies and digital distribution channels, increasing focus on early diagnosis and preventive arthritis care.
Global Arthritic Therapeutic Market Segmentation
1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes 2) By Route Of Administration: Oral, Parenteral, Topical 3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab 2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-1) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors 3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam 4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone 5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat 6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain MedicationsWhat Is The Driver Of The Arthritic Therapeutic Market?
The increasing incidence of arthritis is expected to propel the growth of the arthritic therapeutic market going forward. Arthritis refers to a group of more than 100 conditions characterized primarily by joint pain and inflammation. The incidence of arthritis is growing due to an aging population, increased obesity rates, and lifestyle factors that contribute to joint stress and inflammation. Arthritis treatments alleviate symptoms, reduce inflammation, and improve joint function, enhancing the overall quality of life for those affected. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based government organization, approximately 514,000 people (2.0% of the population) were living with rheumatoid arthritis in 2022. Rheumatoid arthritis made up 2.0% of the total disease burden and represented 16% of the total burden for all musculoskeletal conditions in 2023. Therefore, the increasing incidence of arthritis is driving the growth of the arthritic therapeutic industry.Key Players In The Global Arthritic Therapeutic Market
Major companies operating in the arthritic therapeutic market are Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Arthritic Therapeutic Market Trends and Insights
Major companies operating in the arthritis therapeutic market are focusing on developing innovative solutions such as biosimilar monoclonal antibody-based therapies, to enhance treatment efficacy and reduce costs. Biosimilar monoclonal antibody-based therapies are treatments designed to closely replicate and mimic the effectiveness of original monoclonal antibodies, offering similar therapeutic benefits at a potentially lower cost. For instance, in May 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, launched TOFIDENCE, an intravenous biosimilar monoclonal antibody formulation based on ACTEMRA. TOFIDENCE (tocilizumab-bavi) is developed to be a biosimilar to the reference drug ACTEMRA and is approved for treating moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.What Are Latest Mergers And Acquisitions In The Arthritic Therapeutic Market?
In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics Plc for $27.8 billion. Through this acquisition, Amgen aims to enhance its portfolio of innovative medicines for rare diseases, leveraging Horizon Therapeutics' capabilities to serve more patients globally and drive long-term growth. Horizon Therapeutics plc is an Ireland-based biotechnology company that manufactures and involves arthritic therapies.
Regional Insights
North America was the largest region in the arthritic therapeutic market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Arthritic Therapeutic Market?
The arthritic therapeutics market consists of revenues earned by entities by providing services such as physical therapy services, occupational therapy, diagnostic services, and wellness programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthritic therapeutics market also includes sales of analgesics, joint injections, supplements, and disease-modifying antirheumatic drugs (DMARDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Arthritic Therapeutic Market Report 2026?
The arthritic therapeutic market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the arthritic therapeutic industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Arthritic Therapeutic Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $77 billion |
| Revenue Forecast In 2030 | $97.09 billion |
| Growth Rate | CAGR of 6.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Drug Class, Route Of Administration, Type, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |